T cell therapies have become an integral part of the immuno-oncology landscape since the first CAR T
therapies were approved in 2017. Karen Tkach Tuzman (@_Ktktktktk) discusses how companies are continuing to innovate in CAR T and TCR T cells https://t.co/jAOPFrC4re #celltherapy
Some news on the home front. Many have enjoyed my abuse of the hashtag #Mahockney so many times over the years ;) We’ve decided to live full-time in DC again, so will be selling the glorious old pile https://t.co/p0Zwbt9hvU
But life is long, there are more adventures ahead.
The New Orleans Jazz and Heritage Festival has been canceled for fall 2021 and organizers look to reschedule for spring 2022. Read below for more information: https://t.co/CgNIOE5pZ7
“We would not have triple-drug therapy [for HIV] if it weren’t for [the first approved HIV drug] AZT. But if you stack AZT against triple-drug therapy either for safety or for efficacy, there’s no comparison. So it’s a process, it’s an iterative process.” https://t.co/qPGIfMvuyb
While a Phase 2 trial of prasinezumab was negative overall, positive signals on measures of motor decline earned this antibody a new trial. #parkinsonsdisease@adpdnet https://t.co/oGLZwfTykW
April is #Parkinsonsawarenessmonth (no fooling!) and to welcome its start our CEO @GGKinney joined Moira Gunn to talk about Parkinson’s disease on her latest episode of @biotechnation! Tune into the podcast here: https://t.co/Xc5gDeeZpi